IL213920A0 - 3,3'-spiroindolinone derivatives as anticancer agents - Google Patents

3,3'-spiroindolinone derivatives as anticancer agents

Info

Publication number
IL213920A0
IL213920A0 IL213920A IL21392011A IL213920A0 IL 213920 A0 IL213920 A0 IL 213920A0 IL 213920 A IL213920 A IL 213920A IL 21392011 A IL21392011 A IL 21392011A IL 213920 A0 IL213920 A0 IL 213920A0
Authority
IL
Israel
Prior art keywords
anticancer agents
spiroindolinone derivatives
spiroindolinone
derivatives
anticancer
Prior art date
Application number
IL213920A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL213920A0 publication Critical patent/IL213920A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL213920A 2009-02-17 2011-07-04 3,3'-spiroindolinone derivatives as anticancer agents IL213920A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15308909P 2009-02-17 2009-02-17
PCT/EP2010/051757 WO2010094622A1 (fr) 2009-02-17 2010-02-12 Dérivés de 3, 3' –spiroindolinone utilisés comme agents anticancéreux

Publications (1)

Publication Number Publication Date
IL213920A0 true IL213920A0 (en) 2011-07-31

Family

ID=42062321

Family Applications (1)

Application Number Title Priority Date Filing Date
IL213920A IL213920A0 (en) 2009-02-17 2011-07-04 3,3'-spiroindolinone derivatives as anticancer agents

Country Status (12)

Country Link
US (1) US8217051B2 (fr)
EP (1) EP2398801A1 (fr)
JP (1) JP2012517976A (fr)
KR (1) KR20110104568A (fr)
CN (1) CN102356082A (fr)
AU (1) AU2010215554A1 (fr)
BR (1) BRPI1008899A2 (fr)
CA (1) CA2751767A1 (fr)
IL (1) IL213920A0 (fr)
MX (1) MX2011008176A (fr)
SG (1) SG173629A1 (fr)
WO (1) WO2010094622A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2677045C (fr) 2007-01-31 2016-10-18 Dana-Farber Cancer Institute, Inc. Peptides p53 stabilises et utilisations de ceux-ci
CA2682174C (fr) 2007-03-28 2021-04-06 President And Fellows Of Harvard College Polypeptides cousus
WO2012021876A2 (fr) 2010-08-13 2012-02-16 Aileron Therapeutics, Inc. Macrocycles peptidomimétiques
AU2012226890B2 (en) 2011-03-10 2016-10-06 Daiichi Sankyo Company, Limited Dispiropyrrolidine derivative
CN108929375A (zh) 2011-10-18 2018-12-04 爱勒让治疗公司 拟肽大环化合物
WO2013123267A1 (fr) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Macrocycles peptidomimétiques réticulés par triazole et par thioéther
ES2817877T3 (es) 2012-02-15 2021-04-08 Aileron Therapeutics Inc Macrociclos peptidomiméticos
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
JP6526563B2 (ja) 2012-11-01 2019-06-05 エイルロン セラピューティクス，インコーポレイテッド 二置換アミノ酸ならびにその調製および使用の方法
BR112017005736A2 (pt) 2014-09-24 2017-12-12 Aileron Therapeutics Inc macrociclos peptidomiméticos e formulações dos mesmos
SG10201902594QA (en) 2014-09-24 2019-04-29 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
TWI711452B (zh) 2015-02-20 2020-12-01 日商第一三共股份有限公司 癌症的倂用治療法
CA2979847A1 (fr) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Macrocycles peptidomimetiques et leurs utilisations
EP3284466A4 (fr) 2015-04-13 2018-12-05 Daiichi Sankyo Company, Limited Procédé de traitement combinant un inhibiteur de mdm2 et un inhibiteur de btk
CN108368161A (zh) 2015-09-10 2018-08-03 艾瑞朗医疗公司 作为mcl-1调节剂的拟肽大环化合物
JP2019522633A (ja) 2016-05-20 2019-08-15 ジェネンテック， インコーポレイテッド Ｐｒｏｔａｃ抗体コンジュゲート及び使用方法
TW201818934A (zh) 2016-10-17 2018-06-01 日商第一三共股份有限公司 Ｍｄｍ２抑制劑與ｄｎａ甲基轉移酶抑制劑之倂用治療法
CN115772171A (zh) * 2021-09-09 2023-03-10 沈阳药科大学 一价金催化的螺[吲哚啉-3,3’-哌啶]骨架的合成方法
WO2023056069A1 (fr) 2021-09-30 2023-04-06 Angiex, Inc. Conjugués agent de dégradation-anticorps et leurs procédés d'utilisation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3582890D1 (de) 1984-02-07 1991-06-20 Pfizer 2-oxindolzwischenprodukte.
DE3714473A1 (de) 1987-04-30 1988-11-10 Basf Ag Kontinuierliches verfahren zur epimerisierung von zuckern, insbesondere von d-arabinose zu d-ribose
EP0947511A1 (fr) 1998-03-30 1999-10-06 F. Hoffmann-La Roche Ag Dérivés de l'acide phénoxyacétique et de phénoxyméthyltétrazole ayant une activité antitumorale
EP1087770A4 (fr) * 1998-06-15 2001-11-14 Merck & Co Inc Inhibiteurs de prenyl-proteine transferase
CN1361779A (zh) 1999-07-21 2002-07-31 阿斯特拉曾尼卡有限公司 新化合物
CA2598690C (fr) 2005-02-22 2011-11-15 The Regents Of The University Of Michigan Inhibiteurs de mdm2, sous forme de petites molecules et utilisations de ces derniers
US20070213341A1 (en) * 2006-03-13 2007-09-13 Li Chen Spiroindolinone derivatives
DE602007011902D1 (de) * 2006-03-13 2011-02-24 Hoffmann La Roche Spiroindolinon-derivate
US7495007B2 (en) * 2006-03-13 2009-02-24 Hoffmann-La Roche Inc. Spiroindolinone derivatives
KR20090042779A (ko) 2006-06-30 2009-04-30 쉐링 코포레이션 Ｐ53 활성을 증가시키는 치환된 피페리딘 및 이의 사용
US8466188B2 (en) * 2006-10-12 2013-06-18 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
US7638548B2 (en) 2006-11-09 2009-12-29 Hoffmann-La Roche Inc. Spiroindolinone derivatives
WO2008080822A1 (fr) 2006-12-29 2008-07-10 F. Hoffmann-La Roche Ag Méthodologies d'épimérisation permettant le recueil de stéréoisomères très purs avec un bon rendement
US7553833B2 (en) * 2007-05-17 2009-06-30 Hoffmann-La Roche Inc. 3,3-spiroindolinone derivatives
US7834179B2 (en) * 2007-05-23 2010-11-16 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US7776875B2 (en) 2007-12-19 2010-08-17 Hoffman-La Roche Inc. Spiroindolinone derivatives

Also Published As

Publication number Publication date
WO2010094622A1 (fr) 2010-08-26
US8217051B2 (en) 2012-07-10
EP2398801A1 (fr) 2011-12-28
CA2751767A1 (fr) 2010-08-26
SG173629A1 (en) 2011-09-29
KR20110104568A (ko) 2011-09-22
AU2010215554A1 (en) 2011-07-28
BRPI1008899A2 (pt) 2018-03-13
MX2011008176A (es) 2011-08-17
US20100210674A1 (en) 2010-08-19
CN102356082A (zh) 2012-02-15
JP2012517976A (ja) 2012-08-09

Similar Documents

Publication Publication Date Title
IL213920A0 (en) 3,3'-spiroindolinone derivatives as anticancer agents
ZA201205788B (en) 1,2,4-triazine-4-amine derivatives
IL217208A (en) History of cryptophycin, critophycin conjugates, processes for their preparation, and their use as anticancer agents
IL206765A0 (en) 4,5-dihydro-oxazol-2-yl-amine derivatives
HK1161236A1 (zh) 用作抗癌劑的苯並噻唑衍生物
AP2012006081A0 (en) Lupeol-type triterpene derivatives as antivirals.
AP2012006216A0 (en) Benzimidazole-imidazole derivatives.
PT2562162E (pt) Derivados de n-ciano-4-amino-5-fluoro-pirimidina como fungicidas
SI2598503T1 (sl) Derivati cis-tetrahidro-spiro(cikloheksan-1,1'-pirido(3,4-b)indol)-4-amina
ZA201206630B (en) Hetaryl-[1,8]naphthyridine derivatives
SI2513119T1 (sl) 3,4,4a,10b-tetrahidro-1H-tiopirano-(4,3-c)izokinolinski derivati
MY165626A (en) 1,2,4,-triazolone derivative
IL214427A0 (en) Indole derivatives as anticancer agents
EP2448934A4 (fr) Dérivés de 2-carboxamide-7-piperazinyl-benzofuran
IL218500A0 (en) Apogossypolone derivatives as anticaner agents
ZA201302112B (en) 1,4-oxazepane derivatives
IL212375A0 (en) Naphthamides as anticancer agents
GB2476643B (en) 1,4-Dihydro-1,4-dioxonaphtalene derivatives as anticoagulants
IL208021A0 (en) 2-trifluoromethylnicotinamide derivatives as hdl-cholesterol raising agents
EP2403497A4 (fr) Composés, compositions et utilisation pour une thérapie anticancéreuse
EP2264029A4 (fr) Dérivé de 1,3-dihydroisobenzofurane
HK1162032A1 (en) 1,1,1-trifluoro-2-hydroxypropyl compounds 111--2-
ZA201005346B (en) 3,8-diaminotetrahydroquinoline derivative
EP2105140A4 (fr) Agent anticancéreux
IL219623A0 (en) [1,5]-diazocin derivatives